SCH 52365

· Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SCH 52365, covering 2017-05-15 to 2017-05-15. Get the full timeline:

Most recent: Clinical Trial Update: SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745) [Phase 2]

See pricing